Furthermore, the IC50s of axitinib (p < 0.001), pazopanib (p < 0.001), sorafenib (p < 0.001), and sunitinib (p = 0.0036), the four recommended anti-tumour drugs for the renal cell carcinoma treatment, were lower in patients with higher SHMT2 expression, which suggests that increased SHMT2 expression level was accompanied by increased sensitivity to these four drugs (Figure 6E). Here, SHMT2 is linked to hereditary clear cell renal cell carcinoma.